TY - JOUR
T1 - New Technologies for Outcome Measures in Glaucoma
T2 - Review by the European Vision Institute Special Interest Focus Group
AU - Traber, Ghislaine L.
AU - Della Volpe-Waizel, Maria
AU - Maloca, Peter
AU - Schmidt-Erfurth, Ursula
AU - Rubin, Gary
AU - Roska, Botond
AU - Cordeiro, M. Francesca
AU - Otto, Tilman
AU - Weleber, Richard
AU - Lesmes, Luis Andres
AU - Arleo, Angelo
AU - Scholl, Hendrik P.N.
N1 - Funding Information:
M. della Volpe-Waizel received consultation fees from Novar-tis; P. Maloca is owner of intellectual property on speckle noise analysis and the MIMO OCT discussed in the manuscript and received lecture fees from Heidelberg Engineering® GmbH and Zeiss; U. Schmidt-Erfurth declares to be a consultant for Novartis, Genentech, Boehringer, and Roche; G. Rubin declares that he is a consultant for Pixium Vision SA and MeiraGTxz; M.F. Cordeiro is a named inventor on patents for DARC technology, currently owned by UCL, and is Director of Illustratum Ltd.; T. Otto declares to be Head of Technology Management – Ophthalmic Devices at Heidelberg Engineering® GmbH. R. Weleber declares the following conflicts of interest: Foundation Fighting Blindness: Vice-Chair for Scientific Advisory Board (SAB), Member of Executive Scientific Advisory Board (ESAB) (honorarium received); AGTC: SAB, Co-Investigator for three trials: RPE65 LCA, XLRS1, and CNGB3 ACHR; Consultant (Past): Oxford-Biomedica, Pfizer, and Novartis; Consultant (Current): NightStaRx, QLT, and 4D Molecular Therapeutics; Sanofi: Past PI and now Co-Investigator for two clinical treatment trials: USHSTAT and STARGEN; Holder of US Patent No. 8657446 Visual Field Modeling and Analysis (VFMA). A subset of his presentation material was given at a NEI/ FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Disease held at the NEI in November 2016 [67]. L.A. Lesmes discloses financial, intellectual property, and employment interests in Adaptive Sensory Technology, Inc., which is commercializing novel devices for acuity and CS testing; A. Arleo declares to be the Head of the Essilor-ANR SilverSight Chair and to be a consultant for Essilor. H.P.N. Scholl declares the following conflicts of interest: Data Monitoring Committee: Genentech Inc./F. Hoffmann-La Roche Ltd (CHROMA and SPECTRI trials), Genzyme Corp./Sanofi, and ReNeuron Group Plc/Ora Inc.; Steering Committee: Novo Nordisk (FOCUS trial); Scientific Advisory Board: Astellas Institute for Regenerative Medicine, Gensight Biologics, Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Re-Neuron Group Plc/Ora Inc., Pharma Research & Early Development (pRED) of F. Hoffmann-La Roche Ltd, and Vision Medicines, Inc.; Consultancy: Boehringer Ingelheim Pharma GmbH & Co. KG, Daiichi Sankyo, Inc., Gerson Lehrman Group, Guide-point, and Shire; and Co-Director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB), which is constituted as a nonprofit foundation and receives funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel-Stadt.
Funding Information:
H.P.N. Scholl was supported by an unrestricted grant from Acucela Inc., Aegerion Pharmaceuticals (Novelion Therapeutics), Kinarus AG; NightstaRx Ltd., Ophthotech Corporation, and Spark Therapeutics England, Ltd.; M. della Volpe-Waizel was supported by an unrestricted grant from the SAMW (Schweizerische Akademie der Medizinischen Wissenschaften), SNF (Swiss National Science Foundation), and Bangerter Foundation
Funding Information:
H.P.N. Scholl was supported by an unrestricted grant from Acucela Inc., Aegerion Pharmaceuticals (Novelion Therapeutics), Kinarus AG; NightstaRx Ltd., Ophthotech Corporation, and Spark Therapeutics England, Ltd.; M. della Volpe-Waizel was supported by an unrestricted grant from the SAMW (Schweizerische Aka-demie der Medizinischen Wissenschaften), SNF (Swiss National Science Foundation), and Bangerter Foundation.
Publisher Copyright:
© 2020 S. Karger AG, Basel. Copyright: All rights reserved.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Glaucoma is the leading cause of irreversible blindness worldwide, with an increasing prevalence. The complexity of the disease has been a major challenge in moving the field forward with regard to both pathophysiological insight and treatment. In this context, discussing possible outcome measures in glaucoma trials is of utmost importance and clinical relevance. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on "New Technologies for Outcome Measures in Retina and Glaucoma," addressing both functional and structural outcomes, as well as translational hot topics in glaucoma and retina research. In conjunction with the published literature, this review summarizes the meeting focusing on glaucoma.
AB - Glaucoma is the leading cause of irreversible blindness worldwide, with an increasing prevalence. The complexity of the disease has been a major challenge in moving the field forward with regard to both pathophysiological insight and treatment. In this context, discussing possible outcome measures in glaucoma trials is of utmost importance and clinical relevance. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on "New Technologies for Outcome Measures in Retina and Glaucoma," addressing both functional and structural outcomes, as well as translational hot topics in glaucoma and retina research. In conjunction with the published literature, this review summarizes the meeting focusing on glaucoma.
KW - Glaucoma
KW - Neurodegeneration
KW - Outcome measure
KW - Retinal ganglion cell
KW - Structure-function correlation
UR - http://www.scopus.com/inward/record.url?scp=85078247838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078247838&partnerID=8YFLogxK
U2 - 10.1159/000504892
DO - 10.1159/000504892
M3 - Review article
C2 - 31935739
AN - SCOPUS:85078247838
VL - 63
SP - 88
EP - 96
JO - Ophthalmic Research
JF - Ophthalmic Research
SN - 0030-3747
IS - 2
ER -